Patents by Inventor Hwan Kyu Kang

Hwan Kyu Kang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Quinoline derivatives as inhibitors of AXL/MER RTK and CSF1R
    Patent number: 12162858
    Abstract: The present invention relates to quinoline derivatives which are inhibitors for Axl/Mer RTK (receptor tyrosine kinase) and CSF1R (colony stimulating factor 1 receptor). These compounds are suitable for the treatment of disorders associated with, accompanied by, caused by or induced by Axl/Mer RTK and CSF1R, in particular a hyperfunction thereof. The compounds are suitable for the treatment of hyperproliferative disorders, such as cancer, particularly immune-suppressive cancer (such as those cancers with an immunosuppression of innate immunity in a tumor microenvironment (TME), refractory cancer and cancer metastases. They are also useful in the treatment of inflammatory diseases and/or neurodegenerative diseases.
    Type: Grant
    Filed: May 31, 2019
    Date of Patent: December 10, 2024
    Assignee: QURIENT CO., LTD.
    Inventors: Kiyean Nam, Jaeseung Kim, Dongsik Park, Yeejin Jeon, Yeong-In Yang, Hwan Kyu Kang
  • QUINOLINE DERIVATIVES AS INHIBITORS OF AXL/MER RTK AND CSF1R
    Publication number: 20210163448
    Abstract: The present invention relates to quinoline derivatives which are inhibitors for Axl/Mer RTK (receptor tyrosine kinase) and CSF1R (colony stimulating factor 1 receptor). These compounds are suitable for the treatment of disorders associated with, accompanied by, caused by or induced by Axl/Mer RTK and CSF1R, in particular a hyperfunction thereof. The compounds are suitable for the treatment of hyperproliferative disorders, such as cancer, particularly immune-suppressive cancer (such as those cancers with an immunosuppression of innate immunity in a tumor microenvironment (TME), refractory cancer and cancer metastases. They are also useful in the treatment of inflammatory diseases and/or neurodegenerative diseases.
    Type: Application
    Filed: May 31, 2019
    Publication date: June 3, 2021
    Inventors: KIYEAN NAM, JAESEUNG KIM, DONGSIK PARK, YEEJIN JEON, YEONG-IN YANG, HWAN KYU KANG
  • TOPICAL ANTI-INFLAMMATORY PHARMACEUTICAL COMPOSITION WITH ZILEUTON CREAM FORMULATION
    Publication number: 20180092877
    Abstract: Provided herein is a zileuton cream type topical anti-inflammatory pharmaceutical composition, and more particularly, a zileuton cream type topical anti-inflammatory pharmaceutical composition capable of retaining stability at room temperature and of being applied topically to maximize medical effects while minimizing absorption to an entirety of body, thereby minimizing toxicity caused by the compound so as to be suitable to topical treatment of skin diseases caused by leukotriene.
    Type: Application
    Filed: November 17, 2017
    Publication date: April 5, 2018
    Inventors: Ki Yean NAM, Jeong Jun Kim, Sae Yeon Lee, Ji Ye Ahn, Chunwon Jung, Jaeseung Kim, Hwan Kyu Kang, Hana Kim
  • Topical anti-inflammatory pharmaceutical composition with zileuton cream formulation
    Patent number: 9855243
    Abstract: Provided herein is a zileuton cream type topical anti-inflammatory pharmaceutical composition, and more particularly, a zileuton cream type topical anti-inflammatory pharmaceutical composition capable of retaining stability at room temperature and of being applied topically to maximize medical effects while minimizing absorption to an entirety of body, thereby minimizing toxicity caused by the compound so as to be suitable to topical treatment of skin diseases caused by leukotriene.
    Type: Grant
    Filed: July 21, 2016
    Date of Patent: January 2, 2018
    Assignee: QURIENT CO., LTD.
    Inventors: Ki Yean Nam, Jeong Jun Kim, Sae Yeon Lee, Ji Ye Ahn, Chunwon Jung, Jaeseung Kim, Hwan Kyu Kang, Hana Kim